ao-252
Solid Tumor Malignancies
A2A Pharmaceuticals Inc.Small moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
27 Active assets in the Solid Tumor Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olutasidenib Rigel Pharmaceuticals | Phase 4 | B |
Cyclophosphamide University of Kansas Medical Center | Phase 3 | B |
Pembrolizumab University of Kansas Medical Center | Phase 3 | B |
Epirubicin University of Kansas Medical Center | Phase 3 | B |
Nivolumab University of Kansas Medical Center | Phase 3 | CCC |
View all 35 →
Same molecule, other indications
ao-252 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →